For Patients

?

Lung Cancer Trials

Enspirit

Phase 3 Clinical Trial in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

ENSPIRIT is a company-sponsored Phase 3 trial evaluating the potential of custirsen to improve survival outcomes in patients with advanced or metastatic NSCLC who have progressed after initial chemotherapy treatment has failed. Patients will be randomly selected to receive a second-line standard of care, docetaxel treatment, with or without custirsen therapy. The trial will enroll approximately 1,100 patients with advanced or metastatic NSCLC and is being conducted internationally.

Learn More about the ENSPIRIT trial.

 

Spruce

Phase 2 Clinical Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

Spruce™ is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous NSCLC. Spruce is designed to evaluate the potential benefit of adding apatorsen to carboplatin and pemetrexed therapy by measuring the treatments’ ability to extend time without disease progression. The trial is sponsored by the Sarah Cannon Research Institute (SCRI).

To see if you qualify, visit mytrialmatch.com or call 1-855-216-0159
Learn More about the Spruce Trial.

Cedar

Phase 2 Clinical Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

Cedar™ is an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in combination with gemcitabine and carboplatin in patients with previously untreated, advanced, squamous NSCLC. Cedar is designed to evaluate the potential benefit of adding apatorsen to gemcitabine and carboplatin therapy by measuring the treatments' ability to extend time without disease progression, and other endpoints such as survival, health related quality of life and tumor response rates. This trial is being conducted by the UK National Cancer Research Network and the UK Experimental Cancer Medicine Network and will involve approximately 20 centers in the United Kingdom.

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue